StemSight
Startup
Summarized by Halo AI
StemSight is a Finnish biotech startup developing innovative, off-the-shelf regenerative cell therapies to cure corneal blindness by combining iPS-derived cells with functional biomaterials to restore vision.
Founded & HQ
Tampere, Finland
Company size
11-50 employees
Funding
~$3M
IP status
20 patents filed · 1 grant confirmed
Activity highlights
Secured €2.3 million in seed funding and received a Singapore patent for stem cell technology designed to treat corneal blindness in early 2025
StemSight is a Finnish biotech company founded in 2021, focused on regenerative medicine for eye health. It leverages advanced stem cell technologies and biomaterials to develop off-the-shelf therapies for corneal blindness, with a strong research foundation and growing market presence.
AI summary generated on Jun 22, 2026
OpenAlex
OpenAlexFor general inquiries
LK
Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.